Supernus Pharmaceuticals (NASDAQ:SUPN) Reaches New 52-Week Low – Time to Sell?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) hit a new 52-week low during mid-day trading on Wednesday. The company traded as low as $40.38 and last traded at $40.44, with a volume of 595,855 shares changing hands. The stock had previously closed at $42.01.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, September 21st. Wall Street Zen downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Zacks Research lowered Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, October 5th. Finally, Cantor Fitzgerald raised their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Supernus Pharmaceuticals presently has an average rating of “Hold” and an average target price of $62.40.

Supernus Pharmaceuticals Price Performance

The company’s 50 day simple moving average is $44.22 and its 200 day simple moving average is $46.60. The firm has a market cap of $2.34 billion, a price-to-earnings ratio of -20.93, a P/E/G ratio of 0.79 and a beta of 0.55.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). The company had revenue of $219.06 million for the quarter, compared to analysts’ expectations of $205.31 million. Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%. The firm’s revenue was up 32.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.40 EPS. As a group, analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current year.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Several large investors have recently bought and sold shares of SUPN. Public Employees Retirement System of Ohio acquired a new stake in Supernus Pharmaceuticals in the second quarter valued at approximately $25,000. Rockefeller Capital Management L.P. grew its holdings in Supernus Pharmaceuticals by 354.8% during the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after acquiring an additional 660 shares in the last quarter. Global Retirement Partners LLC acquired a new position in Supernus Pharmaceuticals during the 2nd quarter worth approximately $64,000. Versant Capital Management Inc grew its holdings in Supernus Pharmaceuticals by 47.2% during the 3rd quarter. Versant Capital Management Inc now owns 1,503 shares of the specialty pharmaceutical company’s stock worth $65,000 after acquiring an additional 482 shares in the last quarter. Finally, Nykredit A S purchased a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at approximately $110,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for diseases of the central nervous system (CNS). The company’s portfolio has primarily addressed epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on differentiated formulations and products designed to improve treatment convenience and patient outcomes.

Supernus markets Oxtellar XR (oxcarbazepine extended-release) for the treatment of partial-onset seizures and Trokendi XR (topiramate extended-release) for certain seizure disorders and the prevention of migraine headaches.